Non-transferrin-bound iron induced by myeloablative chemotherapy

British Journal of Haematology

Volumn 99, Issue 2, 1997, Pages 337-343

  Bradley, S J ^a,c   Gosriwitana, I ^b   Srichairatanakool, S ^a   Hider, R C ^b   Porter, J B ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Chemotherapy; Non transferrin bound iron

Indexed keywords

ANTHRACYCLINE; CYTOTOXIC AGENT; DAUNORUBICIN; FERRITIN; IRON; RAZOXANE; TRANSFERRIN; TRANSFERRIN RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; ERYTHROPOIESIS; FEMALE; HODGKIN DISEASE; HUMAN; IRON BINDING CAPACITY; MALE; PRIORITY JOURNAL; RETICULOCYTE; STEM CELL TRANSPLANTATION; TISSUE INJURY;

EID: 0030716163     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1997.4143221.x     Document Type: Article

References (28)

1. Alberts, D.S., Bachur, N.R. & Holtzman, J.L. (1970) The pharmacokinetics of daunomycin in man. Clinical Pharmacology and Therapeutics, 12, 96-105.
2. Al-Refaie, F.N., Wickens, D.G., Wonke, B., Kontoghiorghes, G.J. & Hoffbrand, A.V. (1992) Serum non-transferrin-bound iron in beta-thalassaemia major patients treated with desferrioxamine and L1. British Journal of Haematology, 82, 451-436.
3. Anuwatanakulchai, A., Pootrakul, P., Thuvasethakul, P. & Wasi, P. (1984) Non-transferrin plasma iron in β-thalassaemia/Hb E and haemoglobin H diseases. Scandinavian Journal of Haematology, 32, 153-158.
4. Batey, R.G., Fong, P.L.C. & Sherlock, S. (1978) The nature of serum iron in primary haemochromatosis. Clinical Science, 55, 24P-25P.
5. Beare, S. & Steward, W.P. (1996) Plasma free iron and chemotherapy toxicity. Lancet. 347, 342-343.
6. Beguin, Y., Clemons, G.K., Pootrakul, P. & Fillet, G. (1993) Quantitative assessment of erythropoiesis and functional classification of anemia based on measurements of serum transferrin receptor and erythropoietin. Blood, 81, 1067-1076.
7. Carmine, T.C., Evans, P., Bruchelt, G., Evans, R., Handgretinger, R., Niethammer, D. & Halliwell, B. (1995) Presence of iron catalytic for free radical reactions in patients undergoing chemotherapy: implications for therapeutic management. Cancer Letters, 94, 219-226.
8. Caroline, L., Rosner, F. & Kozinn, P.J. (1969) Elevated serum iron, low unbound transferrin and candidiasis in acute leukemia. Blood, 34, 441-451.
9. Donfrancesco, A., Deb, G., Dominici, C., Angioni, A., Caniglia, M., De Sio, I., Fidani, P., Amici, A. & Helson, I. (1992) Deferoxamine, cyclophosphamide, etoposide, carboplatin, and thiotepa (D-CEaT): a new cytoreductive chelation-chemotherapy regimen in patients with advanced neuroblastoma. American Journal of Clinical Oncology, 15, 319-322.
10. Doroshow, J.H., Locker, G.Y. & Myers, C.E. (1988) Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin. Journal of Clinical Investigation, 65, 128-135.
11. Gordeuk, V.R. & Brittenham, G.M. (1992) Bleomycin-reactive iron in patients with acute non-lymphocytic leukemia. FEBS Letters, 308, 4-6.
12. Gutteridge, J.M.C., Rowley, D.A., Griffiths E. & Halliwell B. (1985) Low-molecular-weight iron complexes and oxygen radical reactions in idiopathic haemochromatosis. Clinical Science, 68, 463-467.
13. Guyader, D., Morel, I., Le Dreau, G., Canva, V., Zanninelli, G., Deugnier, Y. & Brissot, P. (1993) Relationship between plasma non-transferrin-bound iron and the extent of iron overload in genetic hemochromatosis. AASLD, A911.
14. Halliwell, B., Aruoma, O.I., Mufti, G. & Bomford, A. (1988) Bleomycin-detectable iron in serum from leukemic patients before and after chemotherapy. FEBS Letters 241, 202-204.
15. Halliwell, B., Gutteridge, J.M.C. & Cross, C.E. (1992) Free radicals, antioxidants, and human disease: where are we now? Journal of Laboratory and Clinical Medicine, 119, 598-620.
16. Harrison, P., Marwah, S.S., Hughes, R.T. & Bareford, D. (1994) Nontransferrin bound iron and neutropenia after cytotoxic chemotherapy. Journal of Clinical Pathology, 47, 350-352.
17. Herman, E.H. & Ferrans, V.J. (1981) Reduction of chronic doxorubicin cardiotoxicity in dogs by pre treatment with (±)-1,2-bis (3,5-dioxopiperazinyl-1-yl)propane (ICRF-187). Cancer Research, 41, 3436-3440.
18. Hershko, C., Graham, G., Bates, G.W. & Rachmilewitz, E.A. (1978) Non-specific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity. British Journal of Haematology, 40, 255-263.
19. Huebers, H.A., Begiun, Y., Pootrakul, P., Einspahr, D. & Finch, C.A. (1990) Intact transferrin receptors in human plasma and their relation to erythropoiesis. Blood, 75, 102-107.
20. Kongo, Y., Niitsu, Y., Kondo, H., Kato, J., Tsushima, N., Sasaki, K., Hirayama, M., Numata, T., Nishisato, T. & Urushizaki, I. (1987) Serum transferrin receptor as a new index of erythropoiesis. Blood, 70, 1955-1958.
21. Perkins, W.E., Schroder, R.L., Carrano R.A. & Imondi, A.R. (1982) Effect of ICRF-187 on doxorubucin-induced myocardial effects in the mouse and guinea-pig. British Journal of Cancer, 46, 662-667.
22. Perry, A.R., Srichairatanakool, S., McKeag, N., Peniket, A.J., Goldstone, A.H. & Porter, J.B. (1997) Non-transferrin-bound iron (NTBI) persisting in the long-term after bone marrow transplantation (BMT). Bone Marrow Transplantation, 19, (Suppl. S7) 24.
23. Porter, J.B., Abeysinghe, R.D., Marshall, L., Hider, R.C. & Singh, S. (1996) Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy. Blood, 88, 705-713.
24. Singh, S., Hider, R.C. & Porter, J.B. (1990) A direct method for quantification of non-transferrin bound iron (NTBPI). Analytical Biochemistry, 186, 320-323.
25. Speyer, J.L., Green, M.D., Kramer, E., Rey, M., Sanger, J., Ward, C., Dubin, N., Ferrans, V., Stecy, P., Zeleniuch-Jacquotte, A., Wernz, J., Feit, F., Slater, W., Blum, R. & Muggia, F. (1988) Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. New England Journal of Medicine, 319, 745-752.
26. Stasi, R., Zinzani, P.L., Galieni, P., Lauta, V.M., Damasio, E., Dispensa, E., Dammacco, F., Venditti, A., Del Poeta, G., Cantonetti, M., Perrotti, A., Papa, G. & Tura, S. (1995) Clinical implications of cytokine and soluble receptor measurements in patients with newly-diagnosed aggressive non-Hodgkin's lymphoma. European Journal of Haematology, 54, 9-17.
27. Woodcock, T.M., Allegra, J.C., Richman, S.P., Lalley, K., Kubota, T.T., Blumenreich, M.S., Gentile, P., Jones, M. & Seeger, J. (1984) Pharmacology and phase I clinical studies of daunorubicin in patients with advanced malignancies. Seminars in Oncology, 11, (Suppl. 3), 28-32.
28. Worwood, M., Summers, M., Miller, F., Jacobs, A. & Whittaker, J.A. (1974) Ferritin in blood cells from normal subjects and patients with leukaemia. British Journal of Haematology, 28, 27-35.